Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hemophilia
Pharma
With slow sales, BioMarin weighs Roctavian divestiture
BioMarin has now added a divestiture to the list of potential paths for the struggling hemophilia A gene therapy Roctavian.
Zoey Becker
Apr 29, 2024 11:51am
Pfizer charges $3.5M for its first FDA-approved gene therapy
Apr 26, 2024 10:19am
BioTek calls for awareness of safe bleeding disorder drug use
Mar 21, 2024 12:01pm
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
Feb 23, 2024 10:15am
Sanofi partners with pollster to learn about hemophilia patients
Oct 11, 2023 9:00am
UK's NICE unsure about CSL's pricey gene therapy Hemgenix
Aug 2, 2023 8:42am